A potential game changer
ILCT is pioneering a new class of interferon medicines called Hybrid Interferons (HyIFN’s).Interferons are central signalling modulators of the immune system and our hybrids are designed by combining desired features of natural alpha interferon subtypes into novel HyIFN molecules. Hybrid Interferons are designed to deliver enhanced efficacy and improved safety compared to natural IFN subtypes.
The role of Alfacyte™
potential in the global
fight against viral respiratory diseases
Our lead candidate, Alfacyte™, is being developed to combat respiratory viral infections, which pose a major and growing global healthcare threat.
ILCT's Hybrid technology provides the opportunity to design multiple novel HyIFN’s across different therapeutic areas, generating multiple drug candidates.
This breadth of platform opportunity will enable both in-house pipeline development and multiple third-party collaborations.
Dynamic team and
clear business model
ILCT’s executive team and board are globally experienced and have a proven track record of success. Based in BioCity, outside Glasgow, Scotland, and with outreach in London, the company boasts strong academic links with Universities, St Andrews, Edinburgh, Strathclyde and Liverpool School of Tropical Medicine.
Our business Model is to take assets through Phase I/IIa clinical trials then outlicense / sell.
Portfolio of patents
All IP is wholly owned by the company, which possesses a patent portfolio of ten families and continues to grow. These cover composition of matter, DNA sequences, use and geographical locations. Our assets also include Freedom to Operate reports and are antiviral and dermatology cleared.